List of Excipients in Branded Drug PEDIAPRED

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Royal Pharmaceuticals	PEDIAPRED	prednisolone sodium phosphate	68791-104	EDETATE DISODIUM
Royal Pharmaceuticals	PEDIAPRED	prednisolone sodium phosphate	68791-104	METHYLPARABEN
Royal Pharmaceuticals	PEDIAPRED	prednisolone sodium phosphate	68791-104	MONOPOTASSIUM PHOSPHITE
Royal Pharmaceuticals	PEDIAPRED	prednisolone sodium phosphate	68791-104	SODIUM PHOSPHATE, DIBASIC
Royal Pharmaceuticals	PEDIAPRED	prednisolone sodium phosphate	68791-104	SORBITOL

PEDIAPRED Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

Pediapred is an oral prednisolone sodium phosphate product historically marketed as a pediatric liquid corticosteroid. Its commercial value is no longer tied to molecule exclusivity. The opportunity is in differentiated oral-liquid performance: taste, dosing accuracy, preservative and dye positioning, supply reliability, and lower-cost manufacturing.

The strongest product concepts are a ready-to-use, dye-free, alcohol-free, sugar-free prednisolone sodium phosphate solution and a concentrated formulation that reduces administration volume. Neither concept is automatically patentable. Commercial protection would likely depend on formulation claims, manufacturing controls, regulatory differentiation, trademarks, and distribution contracts.

What is Pediapred and which excipient problems matter commercially?

Pediapred contains prednisolone sodium phosphate, a water-soluble corticosteroid used when systemic glucocorticoid treatment is required. The product is intended for oral administration in pediatric and adult patients, with dosing determined by disease, clinical response, and patient characteristics. The historical product has been marketed in oral-solution concentrations that allow liquid dosing in children.

The main excipient issues are:

Excipient or formulation issue	Commercial relevance	Development objective
Sweetener system	Bitter corticosteroid taste can reduce adherence	Improve palatability without excessive sugar or polyols
Flavor system	Pediatric acceptance depends on flavor persistence and aftertaste	Use fruit flavors with low bitterness carryover
Preservative system	Multidose liquids require microbiological protection	Balance preservative efficacy against tolerability
Colorants	Dyes can create parent, physician, or institutional objections	Develop a dye-free version
Polyols and sugars	Sorbitol, sucrose, or similar excipients may create gastrointestinal or dietary concerns	Offer sugar-free and low-osmolality alternatives
Buffer system	pH affects stability, taste, and preservative performance	Optimize pH for chemical and microbiological stability
Viscosity modifiers	Can improve mouthfeel but complicate dosing and manufacturing	Maintain syringe accuracy across temperatures
Container-closure system	Light, oxygen, and moisture can affect stability	Use compatible bottles and oral syringes
Dose concentration	High dosing volumes reduce adherence	Offer a higher-strength solution where clinically and regulatorily appropriate

Pediapred is therefore best viewed as a platform for oral-liquid optimization rather than as a molecule with meaningful remaining patent exclusivity.

What is the FDA regulatory status and Orange Book position of Pediapred?

Pediapred is associated with prednisolone sodium phosphate oral solution under an older FDA-approved prescription-drug framework. The reference product’s regulatory value is its established active ingredient, dosage form, route, and clinical history.

The FDA Orange Book is the controlling source for approved products, therapeutic-equivalence evaluations, and listed patents or exclusivity. For an older prednisolone sodium phosphate oral solution, the relevant commercial conclusion is that the market is generally exposed to generic competition rather than protected by a current new chemical entity period or a substantial brand patent estate.[1]

FDA pathway options

A developer considering a new Pediapred-like product would generally evaluate three pathways:

1. ANDA pathway.
   Appropriate where the applicant can demonstrate pharmaceutical equivalence and bioequivalence to a listed reference product. The product must match the reference product’s active ingredient, dosage form, route, and relevant strength requirements.

2. 505(b)(2) NDA pathway.
   More suitable when the product materially changes formulation, concentration, excipients, delivery volume, container system, or another clinically relevant characteristic that cannot be fully supported through an ANDA.[2]

3. Supplemental or lifecycle strategy.
   Available only to the holder of the underlying approved application and relevant to post-approval changes, labeling, manufacturing, or formulation updates.

A materially differentiated pediatric formulation may be commercially stronger under 505(b)(2), but it would carry greater clinical, CMC, and regulatory expense than a conventional ANDA.

What excipients are most important in a Pediapred formulation?

The excipient strategy should begin with the physicochemical properties of prednisolone sodium phosphate rather than with a generic oral-liquid template. A water-soluble phosphate ester permits solution development, but the formulation still requires control of pH, preservative performance, taste, osmolality, and stability.

Sweeteners and bitterness control

Prednisolone products can have a bitter or medicinal taste. A single high-intensity sweetener may not provide acceptable masking because sweetness can leave the active ingredient’s aftertaste unchanged.

A practical screening program would compare:

• Sucrose-based systems for conventional pediatric palatability.
• Sorbitol or other polyol systems for sugar-free positioning.
• Sucralose, acesulfame potassium, or similar high-intensity sweeteners.
• Blended sweeteners to reduce metallic or lingering aftertaste.
• Flavor combinations such as grape, cherry, berry, or orange.

Polyols can improve mouthfeel but may cause gastrointestinal symptoms at higher exposure. Their use also affects osmolality and can create a commercial disadvantage for patients who require strict dietary control.

Flavor systems

Flavor selection should be tested in the final formulation, not in water alone. Buffer salts, preservatives, sweeteners, and the active ingredient can materially change flavor perception.

A commercially useful product should be tested for:

• Immediate bitterness.
• Delayed aftertaste.
• Flavor persistence after swallowing.
• Acceptance after repeated dosing.
• Compatibility with oral syringes and dosing cups.
• Acceptance across younger children and adolescents.

Pediatric acceptability should be assessed through age-appropriate methods and documented as part of product development. FDA pediatric formulation guidance emphasizes the importance of palatability, dosing flexibility, excipient safety, and age-appropriate administration.[3]

Preservatives

A multidose Pediapred-type product requires a microbiological control strategy. Potential preservative systems may include parabens, benzoate-based systems, or other permitted agents, subject to pH, concentration, packaging, and preservative-effectiveness testing.

The formulation team should avoid treating preservatives as interchangeable. The final selection affects:

• Taste and mouth irritation.
• Compatibility with the container.
• Microbiological robustness after opening.
• Label storage conditions.
• Pediatric exposure.
• Global regulatory acceptability.

A preservative-free product is commercially attractive, but it normally requires unit-dose packaging or another validated microbiological control strategy. The packaging cost can be higher than for a conventional multidose bottle.

Colorants

A dye-free product has a clear market-positioning advantage. Parents, hospitals, and pharmacists increasingly prefer formulations with fewer nonessential excipients. Dye removal can also simplify sourcing and reduce the risk of colorant-specific objections.

The primary challenge is visual differentiation. A dye-free product needs packaging and labeling that prevent dispensing errors between strengths and products.

What formulations are protected by Pediapred-related intellectual property?

The historical Pediapred product is unlikely to have a commercially meaningful active US patent estate. The molecule and conventional oral-liquid dosage form are mature. Patent value would instead arise from a newly developed formulation, packaging system, manufacturing process, or use-specific product profile.

Potential formulation patent claims

A new applicant could evaluate claims directed to:

• A defined prednisolone sodium phosphate concentration.
• A specified pH range.
• A particular sweetener-to-flavor ratio.
• A preservative system with demonstrated stability.
• A low-osmolality pediatric oral solution.
• A dye-free formulation with improved taste masking.
• A high-strength solution that reduces administration volume.
• A unit-dose liquid with defined stability after opening.
• A formulation with improved chemical stability under light or temperature stress.
• A container-closure system that limits adsorption, extractables, or degradation.

Broad claims covering “prednisolone sodium phosphate oral solution” would face serious novelty and obviousness risks because oral solutions of the active ingredient are established. Stronger claims would need a specific formulation combination tied to measurable performance, such as stability, palatability, preservative performance, or dosing accuracy.

Patent durability

A formulation patent filed in 2026 could theoretically receive a term extending into the mid-2040s, subject to the filing date, patent prosecution, terminal disclaimers, and patent-term adjustment. The practical life of the patent would depend on claim scope and whether competitors can design around the excipient combination.

Trade-secret protection may be more effective for flavor ratios, manufacturing order, mixing conditions, and analytical methods that are not disclosed in regulatory filings or patent claims.

How strong is the Pediapred patent estate?

The patent estate is weak as a barrier to conventional generic entry and potentially moderate for a genuinely differentiated formulation.

Asset category	Expected strength for historical Pediapred	Strategic implication
Active ingredient patent	Very low	Prednisolone chemistry is long established
Original oral-solution patent	Low	Conventional solution claims are vulnerable
Method-of-use patents	Low to moderate	Narrow disease or dosing claims may be difficult to enforce
Pediatric formulation patent	Potentially moderate	Requires non-obvious excipient and performance data
Taste-masking patent	Moderate if narrowly defined	Commercial value depends on measurable superiority
Packaging patent	Low to moderate	Useful for unit-dose or stability-specific designs
Trade secrets	Moderate	Flavor and process know-how can delay replication
Trademark protection	Moderate	Supports brand retention but does not block generic substitution

A new formulation should be designed around claims that competitors cannot easily avoid by changing one flavor, preservative, or buffer component.

When does Pediapred lose exclusivity, and what generic entry risks exist?

Pediapred’s principal exclusivity risk has already occurred through product maturity and generic availability. There is no meaningful remaining new chemical entity exclusivity period for prednisolone sodium phosphate oral solution. Generic applicants can compete through ANDA procedures if they can satisfy FDA requirements for pharmaceutical equivalence and bioequivalence.

Generic launch scenarios

Scenario	Product approach	Commercial effect
Low-cost generic solution	Same active ingredient and conventional liquid format	Price erosion and pharmacy substitution
Strength-specific generic	One or more approved concentrations	Stocking gaps may persist for less common strengths
Dye-free generic	Removes colorant while preserving standard formulation	Captures safety- and preference-sensitive buyers
High-strength solution	Reduces dosing volume	Competes on adherence and administration convenience
Unit-dose product	Preservative-free or institution-focused packaging	Targets hospitals, clinics, and specialty pharmacies
505(b)(2) reformulation	New taste, concentration, or packaging profile	Supports differentiated labeling and premium pricing

The principal generic risks are price compression, pharmacy substitution, wholesaler consolidation, and limited physician control over product selection. A branded reformulation needs a concrete reason for pharmacies or caregivers to retain it.

Which companies are challenging Pediapred?

The competitive field is composed mainly of generic manufacturers and liquid-dose suppliers rather than companies pursuing a proprietary Pediapred patent challenge.

Potential competitors include:

• Manufacturers of prednisolone sodium phosphate oral solution.
• Suppliers of prednisolone sodium phosphate oral solutions under generic labels.
• Manufacturers of prednisolone acetate suspensions, which compete for similar corticosteroid use cases but are not formulation equivalents.
• Compounding pharmacies that prepare patient-specific liquid formulations.
• Specialty manufacturers supplying hospital and pediatric institutions.

A Paragraph IV challenge is relevant only if a current Orange Book-listed patent covers the reference product. For an old prednisolone sodium phosphate oral solution with no material listed patent barrier, competition is more likely to proceed through ordinary ANDA approval than through high-value Paragraph IV litigation.[1]

What patent litigation and settlement exposure affects Pediapred?

No major current litigation barrier is associated with the historical Pediapred product’s core active ingredient and conventional oral-solution format. The absence of a meaningful listed patent estate reduces the likelihood of a branded-generic settlement controlling market entry.

Future litigation could arise from:

• A newly patented taste-masking formulation.
• A high-concentration product.
• A unit-dose preservative-free package.
• A method-of-use claim covering a defined pediatric population.
• Trade dress, trademark, or product-name disputes.
• ANDA patent certification disputes involving a newly approved reformulation.

A formulation developer should avoid relying on regulatory exclusivity alone. A 505(b)(2) approval may create three years of approval-related exclusivity for certain changes supported by new clinical investigations, but that exclusivity is narrower than a patent and does not necessarily block all competing products.[2]

What commercial opportunities exist for Pediapred excipients?

The most attractive opportunities are products that solve operational problems for caregivers, pharmacists, hospitals, or payers.

1. Dye-free, sugar-free oral solution

This is the clearest broad-market concept. It could target parents seeking fewer nonessential excipients, patients with dietary restrictions, and institutions standardizing pediatric liquids.

The product should preserve:

• Acceptable flavor.
• Low dosing volume.
• Multidose stability.
• Syringe compatibility.
• Competitive manufacturing cost.

2. High-concentration solution

A higher-strength solution can reduce administration volume and improve adherence. Its main risks are dosing errors and accidental overdose. The package must include a metric oral syringe, clear strength differentiation, and prominent concentration labeling.

A higher concentration may require a new regulatory strategy if it does not correspond to the approved reference product’s strength profile.

3. Preservative-free unit-dose product

Unit-dose packaging can address preservative concerns and reduce contamination risk after opening. It is most commercially relevant to hospitals, emergency departments, pediatric clinics, and specialty pharmacies.

The disadvantages are higher packaging costs, increased logistics volume, and potentially more complex stability studies.

4. Improved taste-masked formulation

Taste masking can support premium positioning if the product demonstrates meaningful preference or adherence benefits. A successful formulation should be evaluated against marketed generic solutions, not only against placebo or a laboratory control.

5. Stable ready-to-use product for institutional use

Hospitals value products with simple storage, rapid dispensing, clear concentration labeling, and low preparation burden. A ready-to-use product may compete effectively even when its acquisition price is higher if it reduces pharmacy compounding and administration steps.

How does Pediapred compare with competing prednisolone products?

Product type	Active ingredient	Physical form	Key excipient issue	Commercial position
Pediapred-type product	Prednisolone sodium phosphate	Oral solution	Taste, preservative, sugar, dye	Pediatric systemic steroid liquid
Prednisolone sodium phosphate generic	Prednisolone sodium phosphate	Oral solution	Price and supply reliability	Direct generic competitor
Prednisolone acetate	Prednisolone acetate	Oral suspension or other dosage forms	Sedimentation and dose uniformity	Alternative formulation, not automatically substitutable
Compounded prednisolone	Variable	Extemporaneous liquid	Stability and standardization	Patient-specific or shortage response
Alternative corticosteroid liquid	Varies	Solution or suspension	Potency, taste, and dosing	Therapeutic alternative, not a direct equivalent

Prednisolone sodium phosphate’s solution format has a technical advantage over suspensions because it avoids sedimentation and shake-dependent dose uniformity. That advantage supports a commercial strategy focused on dosing accuracy and administration convenience.

What geographic opportunities exist?

The United States offers a mature generic market with limited molecule-level exclusivity. International markets may offer greater opportunity where pediatric oral-liquid access is limited, but each jurisdiction has different rules for excipient acceptability, preservative use, pediatric labeling, and bioequivalence.

Priority regions may include markets with:

• High pediatric prescription volume.
• Limited availability of ready-to-use corticosteroid liquids.
• Strong hospital procurement channels.
• Demand for sugar-free or dye-free products.
• Local shortages of commercially manufactured oral solutions.

A global formulation should avoid unnecessary excipient complexity. A flavor and preservative system acceptable in the United States may require reformulation in Europe, Canada, or emerging markets.

What manufacturing and IP barriers affect a new Pediapred product?

The manufacturing process is relatively accessible compared with sterile injectables or biologics, but quality risks remain significant.

Key controls include:

• Complete dissolution of prednisolone sodium phosphate.
• Uniformity throughout the batch.
• pH control.
• Preservative distribution.
• Microbial limits.
• Container-closure compatibility.
• Stability under intended storage conditions.
• Accurate fill volume.
• Syringe dose delivery.
• Control of degradation products.

The largest manufacturing barrier may be reliable supply of child-acceptable flavor, preservative, and packaging components rather than production of the active ingredient. A developer should dual-source critical excipients where possible and qualify alternative suppliers before launch.

Key Takeaways

• Pediapred is a mature prednisolone sodium phosphate oral-liquid product with little remaining molecule-level exclusivity value.
• The commercial opportunity lies in excipient and delivery differentiation.
• The strongest concepts are dye-free, sugar-free, alcohol-free, taste-masked, high-strength, and preservative-free unit-dose formulations.
• A conventional generic is likely to face price competition and pharmacy substitution.
• A differentiated product may require a 505(b)(2) strategy rather than a conventional ANDA.
• Formulation patents should focus on defined excipient combinations and measurable performance, not broad oral-solution claims.
• Taste masking, pH control, preservative selection, osmolality, packaging, and syringe accuracy are the central development issues.
• No major Paragraph IV or settlement-driven entry barrier is expected for the historical Pediapred formulation absent a newly listed patent.
• The best institutional opportunity is a ready-to-use product that reduces compounding, dosing, and contamination risks.
• Trade secrets involving flavor ratios, processing order, and analytical controls may provide more practical protection than broad composition claims.

FAQs

Is Pediapred the same as prednisolone acetate?

No. Pediapred is associated with prednisolone sodium phosphate oral solution. Prednisolone acetate is a different chemical form and may be supplied as a suspension or in other dosage forms. The products are not automatically therapeutically or pharmaceutically equivalent.

Can a company patent a new Pediapred flavor?

A flavor alone is unlikely to provide strong patent protection. A patent position is more credible when the flavor is part of a defined formulation that produces unexpected taste, stability, preservative, or dosing performance.

Is a preservative-free Pediapred formulation commercially attractive?

Yes, particularly for hospitals, pediatric clinics, and caregivers who prefer to avoid preservatives. The product would likely require unit-dose packaging or another validated microbiological-control approach.

Does a high-strength prednisolone solution require a new FDA application?

It may. If the concentration differs from the approved reference product or changes clinically relevant dosing characteristics, the developer may need a 505(b)(2) NDA rather than relying solely on an ANDA.

What is the most defensible commercial differentiation for Pediapred?

The strongest combination is a stable, dye-free, sugar-free, taste-masked oral solution supplied with a calibrated oral syringe and available in a clinically useful concentration. Its commercial success would depend on demonstrated palatability, reliable supply, and a clear pharmacy and caregiver benefit.

References

1. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

2. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-covered-section-505b2

3. U.S. Food and Drug Administration. (2014). Safety and efficacy of excipients for pediatric patients: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-and-efficacy-excipients-pediatric-patients-guidance-industry